Nevro Corp (NYSE:NVRO) – Investment analysts at William Blair issued their Q3 2019 earnings per share (EPS) estimates for Nevro in a research note issued on Tuesday. William Blair analyst M. Kaczor forecasts that the medical equipment provider will post earnings per share of ($0.06) for the quarter.

Other equities research analysts also recently issued research reports about the company. BidaskClub downgraded Nevro from a “hold” rating to a “sell” rating in a report on Saturday, October 28th. TheStreet raised Nevro from a “d+” rating to a “c-” rating in a report on Monday, November 6th. BMO Capital Markets reaffirmed a “buy” rating and set a $100.00 target price on shares of Nevro in a report on Thursday, December 14th. Northland Securities reaffirmed a “buy” rating and set a $96.00 target price on shares of Nevro in a report on Tuesday, November 7th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $110.00 target price (up previously from $105.00) on shares of Nevro in a report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. Nevro has a consensus rating of “Hold” and an average price target of $99.25.

Nevro (NVRO) traded up $0.90 during trading on Wednesday, hitting $78.30. The company had a trading volume of 335,215 shares, compared to its average volume of 560,492. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 6.81. Nevro has a 12-month low of $65.00 and a 12-month high of $99.63. The firm has a market capitalization of $2,290.00, a P/E ratio of -54.00 and a beta of -0.83.

Nevro (NYSE:NVRO) last released its earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.02. Nevro had a negative return on equity of 17.27% and a negative net margin of 14.09%. The firm had revenue of $82.26 million during the quarter, compared to the consensus estimate of $80.50 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. The company’s revenue was up 35.0% compared to the same quarter last year.

In other Nevro news, CFO Andrew H. Galligan sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $75.11, for a total value of $525,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 12.10% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. increased its position in shares of Nevro by 160.5% in the third quarter. Principal Financial Group Inc. now owns 275,383 shares of the medical equipment provider’s stock valued at $25,027,000 after buying an additional 169,683 shares in the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Nevro by 95.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 19,500 shares of the medical equipment provider’s stock valued at $1,625,000 after buying an additional 9,500 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Nevro by 35.4% in the third quarter. Point72 Asset Management L.P. now owns 542,952 shares of the medical equipment provider’s stock valued at $49,343,000 after buying an additional 141,963 shares in the last quarter. Royal Bank of Canada increased its position in shares of Nevro by 11.8% in the second quarter. Royal Bank of Canada now owns 228,687 shares of the medical equipment provider’s stock valued at $17,022,000 after buying an additional 24,101 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Nevro by 2.0% in the second quarter. Vanguard Group Inc. now owns 1,973,146 shares of the medical equipment provider’s stock valued at $146,862,000 after buying an additional 38,553 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “Equities Analysts Issue Forecasts for Nevro Corp’s Q3 2019 Earnings (NVRO)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/19/equities-analysts-issue-forecasts-for-nevro-corps-q3-2019-earnings-nvro.html.

About Nevro

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.